After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
10 September 2024
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
10 September 2024
Patients' expression of CEACAM5 might hold the key to activity after all.
9 September 2024
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
9 September 2024
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
9 September 2024
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
8 September 2024
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
Recent Quick take
- 13 August 2024
- 9 August 2024
- 8 August 2024
- 7 August 2024
- 7 August 2024
- 6 August 2024
- 5 August 2024
- 5 August 2024
- 31 July 2024
- 30 July 2024